Kronos Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
$KRON
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 8, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices including zip code)
Registrant’s telephone number, including area code: (650 ) 781-5200
N/A
(Former name or former address, if changed since last report.)
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of a Material Definitive Agreement.
On April 8, 2025, Kronos Bio, Inc. (the “Company”) entered into a Lease Termination Agreement (the “Termination Agreement”) with MPVCA San Mateo LLC, a California limited liability company (the “Landlord”), pursuant to which the Company and the Landlord agreed to terminate that certain Office Lease, dated July 19, 2018, as amended (the “Original Lease”), related to the Company’s corporate headquarters located at 1300 South El Camino Real, Suite 400, San Mateo, California. Prior to the Termination Agreement, the term of the Original Lease was set to expire on August 31, 2026. Pursuant to the Termination Agreement, the Original Lease will be terminated effective April 30, 2025 (the “Early Termination Date”). The aggregate base rent that would have been payable by the Company to the Landlord from the Early Termination Date through the original expiration date is $1.6 million. As consideration for the Termination Agreement, the Company agreed to pay Landlord approximately $1.4 million, net of $0.1 million of security deposit, on or before the Early Termination Date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KRONOS BIO, INC. | ||||||||||||||
| Dated: April 10, 2025 | By: | /s/ Deborah Knobelman | ||||||||||||
Deborah Knobelman, Ph.D. | ||||||||||||||
| President, Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer | ||||||||||||||